RhoGAM (Rho(D) Immune Globulin)

This is a shot you might get if you're Rh-negative and have been exposed to Rh-positive blood. It helps prevent you from developing antibodies against the Rh factor, which could cause problems in future pregnancies. It's like a shield for your blood.

Brand names:MICRhoGAM, RhoGAM, Rhophylac, WinRho
Medication

What people taking RhoGAM (Rho(D) Immune Globulin) report

Every report comes from a Lived member, sent anonymously.

Have you tried RhoGAM (Rho(D) Immune Globulin) for Hemolytic Disease of the Newborn?

NameHow it went

About RhoGAM (Rho(D) Immune Globulin)

What It's For

Rho(D) immune globulin, best known by the brand name RhoGAM, is an injection that keeps an Rh-negative person's immune system from becoming sensitized to Rh-positive blood. Rh factor is a protein on red blood cells: people who have it are Rh-positive, and people who lack it are Rh-negative. Being Rh-negative causes no health problems on its own. It matters in pregnancy when the baby is Rh-positive, because small amounts of the baby's blood can enter the mother's bloodstream, most often at delivery. Her body may then make antibodies against Rh-positive cells. These rarely affect the current pregnancy, but they stay in the body, and in a later pregnancy they can cross the placenta and attack an Rh-positive baby's red blood cells, causing a serious anemia known as Rh disease. The injection is given during pregnancy and after delivery to Rh-negative women who have not already made these antibodies, unless the baby or the biological father is confirmed to be Rh-negative. It is also used after events that can mix the baby's blood with the mother's, such as amniocentesis, bleeding from a low-lying placenta (placenta previa), a blow to the abdomen, an ectopic pregnancy, a miscarriage or an abortion. Any Rh-negative person who receives Rh-positive blood products in a transfusion may be given it too. For a miscarriage or abortion before 12 weeks, the American College of Obstetricians and Gynecologists (ACOG) has suggested since 2024 that routine Rh testing and treatment can be skipped because the chance of sensitization is very low, although it can still be offered after a conversation about the person's situation. Several brands contain the same active ingredient. RhoGAM and HyperRHO are given into a muscle. Rhophylac and WinRho SDF can be given into a muscle or a vein, and these two have a second, different use: raising platelet counts in some Rh-positive people with immune thrombocytopenia (ITP), an autoimmune condition that causes low platelets and easy bleeding.

How It Works

The injection contains ready-made antibodies against the Rh (D) protein, collected from the plasma of screened donors. When these borrowed antibodies are given soon after Rh-positive red blood cells reach an Rh-negative person's circulation, they suppress the immune response to those cells, so the body does not go on to make its own long-lasting anti-D antibodies. Exactly how this suppression works is still not fully understood. The protection is temporary, because the donated antibodies gradually leave the body over several weeks. That is why each pregnancy and each new exposure is considered separately. The injection also cannot undo sensitization that has already happened: once a person has made their own anti-D antibodies, it no longer helps.

Dosage & Administration

RhoGAM is given by a clinician as a single injection into a muscle. In a typical pregnancy it is used at two points. The first is a routine dose at about 26 to 28 weeks, because small amounts of the baby's blood can reach the mother late in pregnancy without any warning sign. The second comes after birth: if the baby turns out to be Rh-positive, the mother receives another dose within 72 hours of delivery, even if she had the 28-week dose. The after-birth injection is for the mother, never the newborn. If the baby has not arrived 12 weeks after the routine dose, a second dose during pregnancy is recommended. Bleeding, a procedure such as amniocentesis, an injury to the abdomen or a pregnancy loss also calls for a dose within 72 hours. Seventy-two hours is the target rather than a cutoff: if that window has passed, contact the care team anyway, because a later dose may still give some protection. One standard syringe covers the amount of fetal blood that usually crosses over. After delivery or a significant bleed, a blood test can estimate how much of the baby's blood entered the mother's circulation, and extra doses are given if one is not enough. For a pregnancy loss or abortion up to 12 weeks, when treatment is given, a smaller dose may be used. HyperRHO Mini-Dose is labeled for this, and MICRhoGAM, a 50-microgram version of RhoGAM, has been labeled for it, although the current RhoGAM label describes only the standard 300-microgram syringe. Different products are measured in different units (micrograms or international units), so the care team works out the dose for the specific product used.

Side Effects

The most common reactions are at the injection site: soreness, swelling, firmness, redness or warmth, which are typically temporary. Some people notice a slight fever, a rash or body aches. Serious allergic reactions, including anaphylaxis, are uncommon but possible, and they can occur even in someone who has had the injection before without trouble. For this reason it is given where staff and emergency medicines are on hand, and people are watched for at least 20 minutes afterward. Hives, chest tightness, wheezing or feeling faint during or after the injection should be reported to staff at once. If these signs start after leaving, call 911.

Interactions & Warnings

RhoGAM is not given to people who are Rh-positive or to anyone who has had anaphylaxis or another severe reaction to a human immune globulin product. People with IgA deficiency (an inherited lack of one type of antibody) should mention it beforehand, because the product contains a small amount of IgA that could trigger an allergic reaction in them. Because it is made from donated human plasma, it carries a small theoretical risk of passing on an infection. Donors are tested and the manufacturing process includes steps to remove and inactivate viruses, but the risk cannot be eliminated entirely. Immune globulins can weaken the response to live vaccines such as measles, mumps and chickenpox (varicella), so these are generally postponed until 12 weeks after a dose. Vaccination after delivery is the exception: someone who is not immune to rubella or chickenpox should still get the measles, mumps and rubella (MMR) vaccine or the chickenpox vaccine right after birth, and a blood test about three months later can confirm a rubella vaccine took. Let whoever gives a vaccine know about a recent dose. The injected antibodies stay detectable in blood for several weeks and can make an antibody screen or a Coombs test (a test for antibodies on red blood cells) come back positive. This does not mean the person has become sensitized, and it does not rule out further doses when they are needed. RhoGAM comes with a patient identification card that explains this to other providers. A boxed warning applies only to Rhophylac and WinRho SDF when they are given by vein to treat ITP in Rh-positive people. In that setting the antibodies can destroy red blood cells inside the bloodstream, which has caused severe anemia, kidney failure and deaths. These patients are monitored in a healthcare setting for at least 8 hours, with urine tests, and should report back pain, shaking chills, fever, or dark or discolored urine to their care team right away, even after going home. This warning does not apply to Rh-negative people receiving the injection to prevent sensitization.

What to Expect

For most pregnant people, this injection is a routine part of prenatal care. Blood type and an antibody screen are checked early in pregnancy, often at the first prenatal visit. If the results show an Rh-negative blood type with no anti-D antibodies, the 28-week injection is usually scheduled alongside other third-trimester care, and the after-birth dose is arranged in the hospital once the baby's blood type is known. The injection itself takes a moment, followed by a short observation period. The treatment works well when it is given on time. In studies, a dose at 28 weeks plus a dose within 72 hours of delivery lowered the rate of sensitization to about 1 to 2 in 1,000. In the original trial of the after-birth dose, about 6 in 100 untreated women had developed antibodies six months later, compared with about 1 in 800 who received RhoGAM. Available evidence suggests it does not harm the baby or affect future pregnancies, and it can be used while breastfeeding. Because the protection fades, each new pregnancy, and each bleed, procedure or loss within a pregnancy, is assessed again. Keeping the identification card and a record of when doses were given, and making sure each new clinician knows you are Rh-negative, helps the next dose happen on time.

Questions to Ask Your Doctor

  1. 1.What do my blood type and antibody screen show, and would confirming the baby's father's blood type change whether I need this injection?
  2. 2.When will I get the 28-week dose, and how will we know after birth whether I need another one?
  3. 3.If I have bleeding, a fall or a procedure during pregnancy, how quickly should I contact you so a dose can be given within 72 hours?
  4. 4.Do I need a dose after this early miscarriage or abortion, given the newer guidance for losses before 12 weeks?
  5. 5.Are any vaccines I am due for affected by this injection, and should I get the MMR or chickenpox vaccine after delivery?

Last reviewed • Oct 2026

Educational content, not medical advice.